All articles tagged with #biotech funding
Khartis Therapeutics, led by former XinThera executives after Gilead’s acquisition, emerged with a $50M Series B (total funding now $95M) to push an oral IGF-1R inhibitor for thyroid eye disease into clinical trials in Q1 2027, aiming to replace IV therapies like Tepezza and Lumvoa; the company also has other internal programs and strong investor backing.
MeiraGTx secured up to $400 million from Oberland Capital to push its late-stage gene therapies toward launch, anchored by an initial $125 million loan with low single-digit royalties and a $10 million equity stake. The deal also includes up to $50 million in milestones for FDA approvals (one per program for bota-vec and AAV2-hAQP1), up to $100 million more via mutual commitments, and a right for Oberland to buy an additional $15 million in equity. In addition, $50 million could follow a positive AQUAx2 phase 2 readout for dry mouth. Beyond bota-vec and AAV2-hAQP1, MeiraGTx is advancing AAV-GAD for Parkinson’s, with a 2029 follow-up study, and noted a 2025 Lilly license for AAV-AIPL1, highlighting a pipeline with several near-term regulatory milestones.
Scribe Therapeutics filed for a Nasdaq IPO to gauge investor appetite for early-stage biotech and gene-editing startups, backed by major investors including RA Capital, Andreessen Horowitz, OrbiMed and Avoro Capital.
City Therapeutics, a next-gen RNAi startup led by former Alnylam executives, has raised about $99.5 million to fund the clinical development and data collection for its first three RNAi medicines.